Net Cash Provided by (Used in) Financing Activities of Immunovant, Inc. from 31 Mar 2019 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Immunovant, Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Mar 2019 to 30 Jun 2025.
  • Immunovant, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 30 Jun 2025 was $2,918,000, a 325% increase year-over-year.
  • Immunovant, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $454,492,000, a 3.8% decline from 2023.
  • Immunovant, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $472,427,000, a 566% increase from 2022.
  • Immunovant, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $70,885,000, a 65% decline from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Immunovant, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $2,918,000 +$2,232,000 +325% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2026 Q1
Q2 2024 $686,000 -$204,000 -23% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2026 Q1
Q2 2023 $890,000 +$869,000 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2025 Q1
Q2 2022 $21,000* -$70,000 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2024 Q1
Q2 2021 $91,000 -$193,462,000 -100% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022 2023 Q1
Q2 2020 $193,553,000 +$188,250,000 +3550% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q1
Q2 2019 $5,303,000 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q1
Q1 2019 $176,750 01 Jan 2019 31 Mar 2019 10-Q 12 Jun 2019 2019 Q1

Immunovant, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $454,492,000 -$17,935,000 -3.8% 01 Apr 2024 31 Mar 2025 10-K 29 May 2025 2025 FY
2023 $472,427,000 +$401,542,000 +566% 01 Apr 2023 31 Mar 2024 10-K 29 May 2025 2025 FY
2022 $70,885,000 -$129,244,000 -65% 01 Apr 2022 31 Mar 2023 10-K 29 May 2025 2025 FY
2021 $200,129,000 -$182,983,000 -48% 01 Apr 2021 31 Mar 2022 10-K 22 May 2023 2023 FY
2020 $383,112,000 +$236,138,000 +161% 01 Apr 2020 31 Mar 2021 10-K 08 Jun 2022 2022 FY
2019 $146,974,000 +$111,390,000 +313% 01 Apr 2019 31 Mar 2020 10-K 01 Jun 2021 2020 FY
2018 $35,584,000 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.